Study of Recovery of Intestinal CD4+ and Th17 T Cells in HIV-infected Individuals on Short-term Antiretroviral Therapy
Primary Purpose
HIV Infection
Status
Unknown status
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
Tenofovir-Emtricitabine plus Lopinavir/Ritonavir or Darunavir/Ritonavir
Sponsored by
About this trial
This is an interventional basic science trial for HIV Infection focused on measuring HIV infection, GUT, microbial translocation, chronic inflammation, antiretroviral therapy, cART, HAART, Th17, Th1, CD4+
Eligibility Criteria
Inclusion Criteria:
- naïve for antiretroviral treatment
- met the criteria to start cART according to International Guidelines
- written informed consent signed
Exclusion Criteria:
- treatment with glucocorticosteroids and any immune modulating medication for more than seven days in the previous month
- any past or current systemic malignancy, history of inflammatory diseases of the small or large intestine
- pregnancy
- anemia, use of anticoagulants, and any contraindications to phlebotomy or colonoscopy.
Sites / Locations
- Department of Public Health and Infectious Diseases, University of Rome "Sapienza", Italy
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
naïve for cART that met the criteria to start treatment
Arm Description
patients naïve for antiretroviral treatment that met the criteria to start cART according to International Guidelines. These patients will be studied for primary and secondary outcomes after a short term antiretroviral therapy.
Outcomes
Primary Outcome Measures
Difference of number of total Th1 and Th17 CD4+ T-cells (cell/mmc and %) in colon samples between T0 (before start of cARV) and T1 (after 6 months of cARV)
recovery of total Th1 and Th17 CD4+ T-cells (cell/mmc and %) in gut mucosa after 6 months of cARV)
Secondary Outcome Measures
Difference of number of total Th1 and Th17 CD4+ T-cells (cell/mmc and %) in blood samples between T0 (before start of cARV) and T1 (after 6 months of cARV)
recovery of total Th1 and Th17 CD4+ T-cells (cell/mmc and %) in peripheral blood after 6 months of cARV)
Full Information
NCT ID
NCT02097381
First Posted
March 17, 2014
Last Updated
March 26, 2014
Sponsor
University of Roma La Sapienza
Collaborators
Istituto Superiore di Sanità
1. Study Identification
Unique Protocol Identification Number
NCT02097381
Brief Title
Study of Recovery of Intestinal CD4+ and Th17 T Cells in HIV-infected Individuals on Short-term Antiretroviral Therapy
Official Title
HIV Infection and Gut Mucosal Immune Function: Longitudinal Analyses of Intestinal CD4+ and Th17 T Cells in HIV-infected Individuals on Short-term Antiretroviral Therapy
Study Type
Interventional
2. Study Status
Record Verification Date
March 2014
Overall Recruitment Status
Unknown status
Study Start Date
April 2010 (undefined)
Primary Completion Date
March 2014 (Actual)
Study Completion Date
December 2014 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Roma La Sapienza
Collaborators
Istituto Superiore di Sanità
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
HIV infection is associated with a state of chronic, generalized immune activation that has been shown in many studies to be a key predictor of progression to AIDS. The molecular, cellular, and pathophysiological mechanisms underlying the HIV-associated immune activation are complex and still poorly studied. There is, however, growing consensus that both viral and host factors contribute to this phenotype, with emphasis on the role played by the mucosal immune dysfunction (and consequent microbial translocation). Moreover if it is known that in HIV-infected individuals, a severe depletion of intestinal cluster of differentiation 4 (CD4+) T-cells, is associated with loss of epithelium integrity, microbial translocation and systemic immune activation, the kinetics of intestinal CD4+ T-cell reconstitution under combined antiretroviral therapy (cART) remains poorly understood.
This study sought to evaluate the reconstitution of intestinal CD4+ T-cells, including Th1 and Th17, in blood and colon samples collected from HIV-infected individuals before and after a short term cART.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
HIV Infection
Keywords
HIV infection, GUT, microbial translocation, chronic inflammation, antiretroviral therapy, cART, HAART, Th17, Th1, CD4+
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
10 (Actual)
8. Arms, Groups, and Interventions
Arm Title
naïve for cART that met the criteria to start treatment
Arm Type
Other
Arm Description
patients naïve for antiretroviral treatment that met the criteria to start cART according to International Guidelines.
These patients will be studied for primary and secondary outcomes after a short term antiretroviral therapy.
Intervention Type
Drug
Intervention Name(s)
Tenofovir-Emtricitabine plus Lopinavir/Ritonavir or Darunavir/Ritonavir
Other Intervention Name(s)
Truvada, Prezista, Kaletra, Norvir
Intervention Description
Conventional antiretroviral therapy started in naïve patients for antiretroviral treatment that met the criteria to start cART according to International Guidelines.
The antiretroviral treatment consisted in a tenofovir-emtricitabine NRTI backbone (TDF/FTC, 300/200 mg/ml, once a day) plus boosted protease inhibitor, lopinavir/ritonavir (LPV/r, 400/100 mg twice a day) or darunavir/ritonavir (DRV/r 800/100mg once a day).
Primary Outcome Measure Information:
Title
Difference of number of total Th1 and Th17 CD4+ T-cells (cell/mmc and %) in colon samples between T0 (before start of cARV) and T1 (after 6 months of cARV)
Description
recovery of total Th1 and Th17 CD4+ T-cells (cell/mmc and %) in gut mucosa after 6 months of cARV)
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Difference of number of total Th1 and Th17 CD4+ T-cells (cell/mmc and %) in blood samples between T0 (before start of cARV) and T1 (after 6 months of cARV)
Description
recovery of total Th1 and Th17 CD4+ T-cells (cell/mmc and %) in peripheral blood after 6 months of cARV)
Time Frame
6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
naïve for antiretroviral treatment
met the criteria to start cART according to International Guidelines
written informed consent signed
Exclusion Criteria:
treatment with glucocorticosteroids and any immune modulating medication for more than seven days in the previous month
any past or current systemic malignancy, history of inflammatory diseases of the small or large intestine
pregnancy
anemia, use of anticoagulants, and any contraindications to phlebotomy or colonoscopy.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Vincenzo Vullo, MD
Organizational Affiliation
University of Roma La Sapienza
Official's Role
Principal Investigator
Facility Information:
Facility Name
Department of Public Health and Infectious Diseases, University of Rome "Sapienza", Italy
City
Rome
State/Province
RM
ZIP/Postal Code
00161
Country
Italy
12. IPD Sharing Statement
Citations:
PubMed Identifier
25340778
Citation
d'Ettorre G, Baroncelli S, Micci L, Ceccarelli G, Andreotti M, Sharma P, Fanello G, Fiocca F, Cavallari EN, Giustini N, Mallano A, Galluzzo CM, Vella S, Mastroianni CM, Silvestri G, Paiardini M, Vullo V. Reconstitution of intestinal CD4 and Th17 T cells in antiretroviral therapy suppressed HIV-infected subjects: implication for residual immune activation from the results of a clinical trial. PLoS One. 2014 Oct 23;9(10):e109791. doi: 10.1371/journal.pone.0109791. eCollection 2014.
Results Reference
derived
Learn more about this trial
Study of Recovery of Intestinal CD4+ and Th17 T Cells in HIV-infected Individuals on Short-term Antiretroviral Therapy
We'll reach out to this number within 24 hrs